IN2014DN05772A - - Google Patents
Info
- Publication number
- IN2014DN05772A IN2014DN05772A IN5772DEN2014A IN2014DN05772A IN 2014DN05772 A IN2014DN05772 A IN 2014DN05772A IN 5772DEN2014 A IN5772DEN2014 A IN 5772DEN2014A IN 2014DN05772 A IN2014DN05772 A IN 2014DN05772A
- Authority
- IN
- India
- Prior art keywords
- galectin
- medicament
- novel compounds
- compounds
- ligandsin
- Prior art date
Links
- 102000007563 Galectins Human genes 0.000 abstract 3
- 108010046569 Galectins Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 102000000802 Galectin 3 Human genes 0.000 abstract 1
- 108010001517 Galectin 3 Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- -1 propargyl D galactopyranoside derivatives Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12152413.6A EP2620443A1 (en) | 2012-01-25 | 2012-01-25 | Novel galactoside inhibitors of galectins |
| PCT/EP2013/051339 WO2013110704A1 (en) | 2012-01-25 | 2013-01-24 | Novel galactoside inhibitors of galectins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN05772A true IN2014DN05772A (enExample) | 2015-04-10 |
Family
ID=47598867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN5772DEN2014 IN2014DN05772A (enExample) | 2012-01-25 | 2013-01-24 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9353141B2 (enExample) |
| EP (2) | EP2620443A1 (enExample) |
| JP (1) | JP6158840B2 (enExample) |
| CN (1) | CN104066743B (enExample) |
| CA (1) | CA2854986C (enExample) |
| ES (1) | ES2559857T3 (enExample) |
| IN (1) | IN2014DN05772A (enExample) |
| WO (1) | WO2013110704A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1229918B1 (en) | 1999-11-03 | 2008-03-26 | Bristol-Myers Squibb Company | Pharmaceutical composition comprising a combination of metformin and glibenclamide |
| US6586438B2 (en) | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
| US9243021B2 (en) | 2012-10-31 | 2016-01-26 | Galecto Biotech Ab | Galactoside inhibitor of galectins |
| JP6366598B2 (ja) * | 2012-11-15 | 2018-08-01 | タフツ ユニバーシティー | ガレクチンタンパク質阻害剤を用いて被験体の眼の血管新生または繊維症を処置し、調節し、または、予防する方法、組成物、およびキット |
| US9907814B2 (en) | 2012-12-20 | 2018-03-06 | Henry Ford Health System | Method for treating diastolic heart failure by inhibiting galectin-3 |
| US12390486B2 (en) | 2012-12-20 | 2025-08-19 | Henry Ford Health System | Method for treating diastolic heart failure by inhibiting galectin-3 |
| EP3415522A1 (en) * | 2014-07-09 | 2018-12-19 | Galecto Biotech AB | Novel hybrid galactoside inhibitor of galectins |
| EP3250581B1 (en) * | 2015-01-30 | 2021-01-20 | Galecto Biotech AB | Alpha-d-galactoside inhibitors of galectins |
| WO2017152048A1 (en) * | 2016-03-04 | 2017-09-08 | Galectin Sciences, Llc | Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof |
| US10889610B2 (en) * | 2016-07-12 | 2021-01-12 | Galecto Biotech Ab | Alpha-D-galactoside inhibitors of galectins |
| EP3484903A1 (en) * | 2016-07-12 | 2019-05-22 | Galecto Biotech AB | Alpha-d-galactoside inhibitors of galectins |
| KR102626669B1 (ko) | 2017-05-12 | 2024-01-17 | 갈랙틴 사이언시즈, 엘엘씨 | 질환의 예방 및 치료를 위한 화합물 및 이의 용도 |
| KR20200104889A (ko) | 2017-12-29 | 2020-09-04 | 글리코미메틱스, 인크. | E-셀렉틴 및 갈렉틴-3의 이종이기능성 억제제 |
| AU2019293857A1 (en) | 2018-06-29 | 2020-12-10 | Glykos Finland Oy | Conjugates |
| CN118373810A (zh) | 2018-12-27 | 2024-07-23 | 糖模拟物有限公司 | 抑制c-糖苷的半乳凝素-3 |
| US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
| ES2974680T3 (es) * | 2019-08-09 | 2024-07-01 | Idorsia Pharmaceuticals Ltd | Derivados de (2-acetamidil)tio-beta-D-galactopiranósidos |
| WO2021123506A1 (en) | 2019-12-18 | 2021-06-24 | Glykos Biomedical Oy | Stabile conjugate |
| CN116270672A (zh) * | 2023-02-27 | 2023-06-23 | 江苏科技大学 | β-D-硫代葡萄糖钠盐在制备缓解或治疗急性肾损伤的药物中的应用 |
| CZ2023132A3 (cs) | 2023-04-04 | 2024-10-16 | Ústav Chemických Procesů Av Čr, V. V. I. | Komplexy ruthenia pro inhibici galektinů, způsob jejich výroby a jejich použití |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100172D0 (sv) * | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| CA2724064C (en) | 2008-05-16 | 2016-05-17 | Forskarpatent I Syd Ab | Synthesis of galactoside inhibitors |
| EP2424873B1 (en) | 2009-04-28 | 2017-11-15 | Galecto Biotech AB | Novel galactoside inhibitors of galectins |
| EP3278805A1 (en) | 2012-10-31 | 2018-02-07 | Galecto Biotech AB | Diagnosing pulmonary fibrosis |
-
2012
- 2012-01-25 EP EP12152413.6A patent/EP2620443A1/en not_active Withdrawn
-
2013
- 2013-01-24 WO PCT/EP2013/051339 patent/WO2013110704A1/en not_active Ceased
- 2013-01-24 CA CA2854986A patent/CA2854986C/en not_active Expired - Fee Related
- 2013-01-24 US US14/364,169 patent/US9353141B2/en not_active Expired - Fee Related
- 2013-01-24 EP EP13700935.3A patent/EP2807176B1/en not_active Not-in-force
- 2013-01-24 CN CN201380006432.7A patent/CN104066743B/zh not_active Expired - Fee Related
- 2013-01-24 ES ES13700935.3T patent/ES2559857T3/es active Active
- 2013-01-24 IN IN5772DEN2014 patent/IN2014DN05772A/en unknown
- 2013-01-24 JP JP2014553715A patent/JP6158840B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013110704A1 (en) | 2013-08-01 |
| ES2559857T3 (es) | 2016-02-16 |
| US20140336146A1 (en) | 2014-11-13 |
| CA2854986A1 (en) | 2013-08-01 |
| CA2854986C (en) | 2019-09-17 |
| CN104066743B (zh) | 2016-04-06 |
| US9353141B2 (en) | 2016-05-31 |
| JP2015504909A (ja) | 2015-02-16 |
| EP2620443A1 (en) | 2013-07-31 |
| EP2807176B1 (en) | 2015-12-30 |
| EP2807176A1 (en) | 2014-12-03 |
| CN104066743A (zh) | 2014-09-24 |
| JP6158840B2 (ja) | 2017-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN05772A (enExample) | ||
| AU2012214029A8 (en) | Rorgammat inhibitors | |
| MY160241A (en) | 5-alkynyl-pyrimidines | |
| EA024702B8 (ru) | Новые иммуномодуляторные и противовоспалительные соединения | |
| MD20140002A2 (ro) | Indazoli | |
| WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| NZ603789A (en) | Heteroaryl compounds and methods of use thereof | |
| MX2013004491A (es) | Boronatos como inhibidores de arginasa. | |
| PH12016500225A1 (en) | Novel quinoline-substituted compound | |
| IN2014MN02459A (enExample) | ||
| PH12015501116A1 (en) | New indanyloxydihydrobenzofuranylacetic acids | |
| TN2014000016A1 (en) | 4 - piperidinyl compounds for use as tankyrase inhibitors | |
| PH12015500211A1 (en) | 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | |
| HK1211947A1 (en) | Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors | |
| UA111628C2 (uk) | Композиція для боротьби з хворобою рослини та її застосування | |
| MX342924B (es) | Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas. | |
| IN2015DN01151A (enExample) | ||
| MX2014004858A (es) | Compuestos de 3,4-diamino-3-ciclobuten-1,2-diona disustituidos utiles en el tratamiento de patologias mediadas por quimiocinas. | |
| MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
| MX340577B (es) | Inhibidor de fosfoinositida 3-quinasa con una porcion de enlace de cinc. | |
| MX349548B (es) | Compuestos de tienopirimidina. | |
| MX2014002988A (es) | Proceso y composicion para inhibir la polimerizacion de compuestos de ciclopentadieno. | |
| PH12012501945A1 (en) | Use of novel pan-cdk inhibitors for treating tumors | |
| MX2013006670A (es) | Derivado de 2-carboxamida-4-piperazinil-benzofurano. | |
| MX2014009084A (es) | Derivados de pirimidooxazocina como inhibidores de mtor. |